Translation and validation of the Swedish version of the early-onset scoliosis 24-item questionnaire.

IF 1.6 Q3 CLINICAL NEUROLOGY

Spine deformity Pub Date : 2025-07-01 Epub Date: 2025-03-07 DOI:10.1007/s43390-025-01064-5

I Green-Petersen, T Cheng, S Blixt, P Gerdhem

{"title":"Translation and validation of the Swedish version of the early-onset scoliosis 24-item questionnaire.","authors":"I Green-Petersen, T Cheng, S Blixt, P Gerdhem","doi":"10.1007/s43390-025-01064-5","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to translate and validate the Early-Onset Scoliosis 24-Item Questionnaire (EOSQ-24) into Swedish.Methods: Following international guidelines, the EOSQ-24 was double forward translated by independent translators, reviewed by experts, and distributed to caregivers. A single back translation was performed, and the Swedish version was finalized. The Swedish EOSQ-24 was made available online for clinically active spinal surgeons to use during outpatient visits, where it was distributed to caregivers of early-onset scoliosis (EOS) patients aged 0-15 years. Internal consistency was assessed using Cronbach's alpha, item-total correlation, and analysis of floor and ceiling effects. Convergent validity was examined using the EuroQol-5D 3 level (EQ-5D) and the Scoliosis Research Society 22-Item Questionnaire revised (SRS-22r).Results: Responses from 140 caregivers were collected. Ceiling effects ranged from 21 to 74%, with no floor effects > 15%. Internal consistency was excellent (Cronbach's alpha = 0.9), except for two domains: \"General Health\" (0.6) and \"Pulmonary Function\" (0.4). The item-total correlation was poor for \"Pulmonary Function\". EOSQ-24 domains showed significant convergent validity with SRS-22r (Spearman's rho 0.5 to 0.8) and the EQ-5D (Spearman's rho -0.6 to -0.8). Stepwise regression showed lower scores for patients with neuromuscular scoliosis, indicating sensitivity for scoliosis etiology.Conclusion: The Swedish EOSQ-24 is a valid, disease-specific questionnaire with excellent internal consistency suitable for use in a clinical setting. Minor inconsistencies are not unique for the Swedish translation.Level of evidence: II.","PeriodicalId":21796,"journal":{"name":"Spine deformity","volume":" ","pages":"1253-1261"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227347/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spine deformity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s43390-025-01064-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to translate and validate the Early-Onset Scoliosis 24-Item Questionnaire (EOSQ-24) into Swedish.

Methods: Following international guidelines, the EOSQ-24 was double forward translated by independent translators, reviewed by experts, and distributed to caregivers. A single back translation was performed, and the Swedish version was finalized. The Swedish EOSQ-24 was made available online for clinically active spinal surgeons to use during outpatient visits, where it was distributed to caregivers of early-onset scoliosis (EOS) patients aged 0-15 years. Internal consistency was assessed using Cronbach's alpha, item-total correlation, and analysis of floor and ceiling effects. Convergent validity was examined using the EuroQol-5D 3 level (EQ-5D) and the Scoliosis Research Society 22-Item Questionnaire revised (SRS-22r).

Results: Responses from 140 caregivers were collected. Ceiling effects ranged from 21 to 74%, with no floor effects > 15%. Internal consistency was excellent (Cronbach's alpha = 0.9), except for two domains: "General Health" (0.6) and "Pulmonary Function" (0.4). The item-total correlation was poor for "Pulmonary Function". EOSQ-24 domains showed significant convergent validity with SRS-22r (Spearman's rho 0.5 to 0.8) and the EQ-5D (Spearman's rho -0.6 to -0.8). Stepwise regression showed lower scores for patients with neuromuscular scoliosis, indicating sensitivity for scoliosis etiology.

Conclusion: The Swedish EOSQ-24 is a valid, disease-specific questionnaire with excellent internal consistency suitable for use in a clinical setting. Minor inconsistencies are not unique for the Swedish translation.

Level of evidence: II.

查看原文本刊更多论文

瑞典版早发性脊柱侧凸24项问卷的翻译与验证。

目的：本研究旨在将早发型脊柱侧凸24项问卷（EOSQ-24）翻译并验证为瑞典语。方法：根据国际指南，EOSQ-24由独立翻译人员进行双前翻译，经专家评审，并分发给护理人员。进行了一次反向翻译，瑞典语版本最终定稿。瑞典EOSQ-24在网上提供给临床活跃的脊柱外科医生在门诊就诊时使用，在那里它被分发给0-15岁早发性脊柱侧凸（EOS）患者的护理人员。内部一致性评估采用Cronbach’s alpha、项目-总量相关性和下限和上限效应分析。采用EuroQol-5D 3水平（EQ-5D）和脊柱侧凸研究学会22题问卷修订（SRS-22r）检验收敛效度。结果：收集了140名护理人员的反馈。天花板效果从21%到74%不等，没有地板效果的比例为15%。内部一致性非常好（Cronbach's alpha = 0.9），除了两个领域：“一般健康”（0.6）和“肺功能”（0.4）。“肺功能”的项目-总相关性较差。EOSQ-24结构域与SRS-22r （Spearman's rho 0.5 ~ 0.8）和EQ-5D （Spearman's rho -0.6 ~ -0.8）具有显著的收敛效度。逐步回归显示神经肌肉型脊柱侧凸患者得分较低，说明对脊柱侧凸病因敏感。结论：瑞典EOSQ-24是一份有效的疾病特异性问卷，具有良好的内部一致性，适合在临床环境中使用。轻微的不一致并不是瑞典语翻译所独有的。证据水平：II。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Spine deformity

CiteScore

3.20

自引率

18.80%

发文量

167

期刊介绍： Spine Deformity the official journal of the?Scoliosis Research Society is a peer-refereed publication to disseminate knowledge on basic science and clinical research into the?etiology?biomechanics?treatment?methods and outcomes of all types of?spinal deformities. The international members of the Editorial Board provide a worldwide perspective for the journal's area of interest.The?journal?will enhance the mission of the Society which is to foster the optimal care of all patients with?spine?deformities worldwide. Articles published in?Spine Deformity?are Medline indexed in PubMed.? The journal publishes original articles in the form of clinical and basic research. Spine Deformity will only publish studies that have institutional review board (IRB) or similar ethics committee approval for human and animal studies and have strictly observed these guidelines. The minimum follow-up period for follow-up clinical studies is 24 months.